23andMe wants to go private. It’s the latest in a line of failed SPACs
Fast CompanyLike a number of companies that went public during the pandemic, 23andMe has for months been trying to manage a terrible case of SPAC-itis, an inflammation that causes plunging stock values due to the business being, as one analyst put it, not “…